Abstract
The objective of the present study was to assess the rate of side-effects and dose-limiting toxicity in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX) at an initial dose of 15 or 25 mg/week. One hundred and eighty-five patients with active RA were enrolled into a prospective non-blind trial over 12 months and randomized to start at a dose of 15 mg/week with subsequent increases if necessary (group A) or 25 mg/week with subsequent dose reductions according to effect (group B). With 168 patients eligible for evaluation 74% of patients in group A and 73% of patients in group B were on MTX after 12 months. Withdrawal due to side-effects amounted to 16% of patients in group A and 18% in group B, and decreases in dose due to side-effects amounted to 10% in group A and 9% in group B. The higher dose of MTX elicited a significantly higher rate of gastrointestinal side-effects (28% versus 17%, P<0.05) and a tendency towards a higher rate of liver enzyme elevations (47% versus 39%). The frequencies of other side-effects did not differ significantly between the groups. We concluded that starting MTX treatment at a dose of 25 mg/week was associated with a higher rate of minor but not major toxicity as compared with 15 mg/week. With this profile of tolerability it is possible to examine the therapeutic potential of MTX doses exceeding 15 mg/week.
Similar content being viewed by others
References
Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818–882
Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL (1985) Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 103:489–496
Williams HJ, Willkens RF, Samuelson CO, Alarcon GS, Guttdauria M, Yarboro C, Polisson RP, Weiner SR, Luggen ME, Billingsley LM, Dahl SL, Egger MJ, Reading JC, Ward JR (1985) Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 28:721–730
Willkens RF, Urowitz MB, Stablein DM, McKendry RJR, Berger RG, Box JH, Fiechtner JJ, Fudman EJ, Hudson NP, Marks CR, Brooks R, Rooney TW, Rubin BR, Schmid FR, Segal AM, Thomas JW, Goldstein AG, Yunus MB, Wortmann RL, Sherrer YRS (1992) Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum 35:849–856
Jeurissen MEC, Boerbooms ANT, van de Putte LBA, Doesburg WH, Mulder J, Rasker JJ, Kruijsen MWM, Haverman JF, van Beusekom HJ, Muller WH, Franssen MJAM, de Rooy DJRAM (1991) Methotrexate versus azathioprine in the threatment of rheumatoid arthritis. Arthritis Rheum 34:961–972
Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, Anderson L, Block S, Irby R, Wolfe F, Gall E, Torretti D, Biundo J, Small R, Coblyn J, Polisson R (1990) Low-dose methotrexate compared with auranofin in aduld rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum 33:330–338
Menninger H, Herborn G, Rau R, Elhardt D, Schmitt J (1992) Randomised study of methotrexate vs. gold sodium thiomalate in patients with active rheumatoid arthritis. Arthritis Rheum 35 [Suppl]:S147
Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL, Weisman MH, Willkens RF, Singer JZ, Alarcon GS, Field EH, Clements PJ, Russell IJ, Hochman RF, Boumpas DT, Marble DA (1992) Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum 35:259–269
Rau R, Herborn G, Karger T, Werdier D (1991) Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy. Arthritis Rheum 34:1236–1244
Jeurissen MEC, Boerbooms AMT, van de Putte LBA, Doesburg WH, Lemmens AM (1991) Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. Ann Intern Med 114:999–1004
Weinblatt M, Polisson R, Blotner S, Sosman L, Aliabadi P, Baker N, Weissman B (1993) The effects of drug therapy on radiologic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 36:613–619
Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I (1989) Increasing methotrexate effects with increasing dose in the treatment or resistant rheumatoid arthritis. J Rheumatol 16:313–320
Gabriel S, Gregan E, O'Fallon M, Jaquith J, Bunch T (1990) Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. J Rheumatol 17:460–465
Bauer H, Breitbart A, Pezzutto A (1992) Therapierefraktäre rheumatoide Arthritis: Intensivierung der Methotrexat-Basistherapie durch intravenöse Gabe. Z Rheumatol 51 [Suppl]: 57
Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS (1984) A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 11:760–763
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PFJ (1993) Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 20:639–644
Tishler M, Caspi D, Yaron M (1993) Long-term experience with low dose methotrexate in rheumatoid arthritis. Rheumatol Int 13:103–106
Morand EF, McCloud PI, Littlejohn GO (1992) Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 19:704–708
Pincus T, Marcum SB, Callahan LF (1992) Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. second line drugs and prednisone. J Rheumatol 19:1885–1884
Sany J, Anaya JM, Luissez V, Couret M, Combe B, Daures J-P (1991) Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. J Rheumatol 18:1323–1327
Wolfe F, Hawley DJ, Cathey MA (1990) Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 17:994–1002
Mielants H, Veys EM, van der Straten C, Ackerman C, Goemaere S (1991) The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: An open prospective study. J Rheumatol 18:978–983
McKendry RIR, Cyr M (1989) Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. Arch Med 149:685–689
Rau R, Karger T, Herborn G, Frenzel H (1989) Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. J Rheumatol 16:489–493
Aponte J, Petrelli M (1988) Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Arthritis Rheum 31:1457–1464
Tishler M, Caspi D, Halperin Z, Baratz M, Moshkowitz M, Yaron M (1992)_A prospective analysis of liver biopsies in rheumatoid arthritis patients receiving long term methotrexate therapy. Rheumatol Int 12:39–41
Kremer JM, Lee RG, Tolman KG (1989) Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 32:121–127
Shergy WJ, Phillips RM, Hunt RE (1992) Pulmonary toxicity following chronic methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 32 [Suppl]: R17
St Clair EW, Rice JC, Snyderman R (1985) Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med 145:2035–2038
Searles G, McKendry RJR (1987) Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 14:1164–1171
Hanrahan PS, Scrivens GA, Russell AS (1989) Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol 28:147–153
Cannon GW, Ward JR, Clegg DO, Samuelson CO, Abbott TM (1983) Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 26:1269–1274
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schnabel, A., Reinhold-Keller, E., Willmann, V. et al. Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. Rheumatol Int 14, 33–38 (1994). https://doi.org/10.1007/BF00302669
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00302669